Before the era of targeted therapy and immune checkpoint therapy, BRAF p.V600E was associated with inferior outcomes while MMR deficiency was associated with superior outcomes (20, 43, 51, 52). Here, BRAF is linked to mismatch repair cancer syndrome 1.